Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants.

Trial Profile

Safety and Tolerability of Aclidinium Administered Intravenously and Absolute Bioavailability of Inhaled Aclidinium in Healthy Male Participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 May 2011

At a glance

  • Drugs Aclidinium bromide; Aclidinium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Almirall S.A.; Forest
  • Most Recent Events

    • 31 May 2011 Results published in the Journal of Clinical Pharmacology.
    • 21 Oct 2010 New trial record
    • 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top